Phase 1 Results Reported for Anti-LINGO-1 Remyelination Agent
نویسندگان
چکیده
منابع مشابه
Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies
Objective To evaluate whether the anti-LINGO-1 antibody has immunomodulatory effects. Methods Human peripheral blood mononuclear cells (hPBMCs), rat splenocytes, and rat CD4+ T cells were assessed to determine whether LINGO-1 was expressed and was inducible. Anti-LINGO-1 Li81 (0.1-30 μg/mL) effect on proliferation/cytokine production was assessed in purified rat CD4+ T cells and hPBMCs stimul...
متن کاملStructure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
Multiple sclerosis (MS) is an autoimmune-inflammatory disease of the central nervous system (CNS) with prominent demyelination and axonal injury. While most MS therapies target the immunologic response, there is a large unmet need for treatments that can promote CNS repair. LINGO-1 (leucine-rich repeat and Ig-containing Nogo receptor interacting protein-1) is a membrane protein selectively expr...
متن کاملRandomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033
OBJECTIVE To evaluate the safety, tolerability, and pharmacokinetics (PK) of BIIB033 (anti-LINGO-1 monoclonal antibody) in healthy volunteers and participants with multiple sclerosis (MS). METHODS In 2 separate randomized, placebo-controlled studies, single ascending doses (SAD; 0.1-100 mg/kg) of BIIB033 or placebo were administered via IV infusion or subcutaneous injection to 72 healthy volu...
متن کاملExposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration.
LINGO-1 (leucine-rich repeat and Ig domain containing NOGO receptor interacting protein-1) is a negative regulator of myelination and repair of damaged axons in the central nervous system (CNS). Blocking LINGO-1 function leads to robust remyelination. The anti-LINGO-1 Li81 antibody is currently being evaluated in clinical trials for multiple sclerosis (MS) and is the first MS therapy that direc...
متن کاملLingo-1: a novel target in therapy for Alzheimer's disease?
Unraveling the causes underlying Alzheimer's disease (AD) is certainly one of the greatest challenges of this century for researchers. With advances in medicine and technology, the world is experiencing a demographic shift towards a growing elderly population. With this increasingly ageing population, the number of individuals being affected by AD is booming. AD has a significant negative impac...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Discovery Forum
سال: 2014
ISSN: 2165-9893
DOI: 10.7493/msdf.10.13244.1